<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/79FAC19E-F649-4430-810F-8848DD1E1FF7"><gtr:id>79FAC19E-F649-4430-810F-8848DD1E1FF7</gtr:id><gtr:name>Spanish National Cancer Research Center</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4B6C2A2B-0BBF-4E20-B1B7-5226C468099C"><gtr:id>4B6C2A2B-0BBF-4E20-B1B7-5226C468099C</gtr:id><gtr:name>Rockefeller University</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:department>School of Medicine</gtr:department><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/83D87776-5958-42AE-889D-B8AECF16B468"><gtr:id>83D87776-5958-42AE-889D-B8AECF16B468</gtr:id><gtr:name>University of Leeds</gtr:name><gtr:address><gtr:line1>University of Leeds</gtr:line1><gtr:line4>Leeds</gtr:line4><gtr:line5>West Yorkshire</gtr:line5><gtr:postCode>LS2 9JT</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/79FAC19E-F649-4430-810F-8848DD1E1FF7"><gtr:id>79FAC19E-F649-4430-810F-8848DD1E1FF7</gtr:id><gtr:name>Spanish National Cancer Research Center</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4B6C2A2B-0BBF-4E20-B1B7-5226C468099C"><gtr:id>4B6C2A2B-0BBF-4E20-B1B7-5226C468099C</gtr:id><gtr:name>Rockefeller University</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/24443F81-A2F2-42C7-996E-7E4908C4E4C2"><gtr:id>24443F81-A2F2-42C7-996E-7E4908C4E4C2</gtr:id><gtr:firstName>Reuben</gtr:firstName><gtr:surname>Tooze</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G108%2F500"><gtr:id>5F6EEF97-9A41-4465-AD64-0B0BE0DA75CB</gtr:id><gtr:title>Does deregulated activation of Rho family G-proteins define a novel subgroup of B cell malignancy, with shared molecular</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G108/500</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2007-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2003-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>623085</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Spanish National Cancer Research Center</gtr:collaboratingOrganisation><gtr:country>Spain, Kingdom of</gtr:country><gtr:description>Roncador lab</gtr:description><gtr:id>9ABB5C04-C74A-4E15-B897-C2923B76E8F2</gtr:id><gtr:impact>19176362</gtr:impact><gtr:outcomeId>874DC007C02-1</gtr:outcomeId><gtr:partnerContribution>Generation and access to a unique set of monoclonal antibodies.</gtr:partnerContribution><gtr:piContribution>We generated a set of fusion proteins to the activated form of the transcription factor XBP1s. We evaluated the specificity of the resulting monoclonal antibodies by IHC and WB. I contributed extensively to the writing of the resulting manuscript.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Gurdon Institute</gtr:department><gtr:description>Surani Lab</gtr:description><gtr:id>1231787A-CB49-4DBF-AB61-2C361A07FC9F</gtr:id><gtr:impact>18953407</gtr:impact><gtr:outcomeId>2002B6E276C-1</gtr:outcomeId><gtr:piContribution>We provided access to a unique antibody to BLIMP1 and to unpublished data regarding target genes, we validated the promoter of a specific target gene as a direct target of BLIMP1 which constituted a supplemental figure in the paper.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Rockefeller University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Laboratory of Mammalian Cell Biology and Development Rockefeller</gtr:department><gtr:description>Fuchs Lab Rockefeller</gtr:description><gtr:id>51E92A16-78F2-45DE-8B1B-EDFACF92AA67</gtr:id><gtr:impact>16901790</gtr:impact><gtr:outcomeId>78564A0D415-1</gtr:outcomeId><gtr:partnerContribution>The publication has raised the profile of the laboratory and resulted in numerous requests for our reagents from Europe, USA and Australia.</gtr:partnerContribution><gtr:piContribution>Raised a unique antibody to the transcription factor BLIMP1, and described the expression pattern in human skin. Using this information I pro-actively contacted the Fuchs lab, to ask about establishing a collaboration. I provided the antibody, lentiviral and normal expression vectors for BLIMP1 and promoter reporter constructs. I provided advice on a murine phenotype, based on the observed expression patterns in human.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>LLR Project grant</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>71FE5B3A-0C42-4F5E-86D3-AE084B641518</gtr:id><gtr:outcomeId>ZWdz671NiKc0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1300000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK Senior Clinical Fellowship</gtr:description><gtr:end>2014-12-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>1EFE27C2-2AB2-4011-B618-302F17A0279A</gtr:id><gtr:outcomeId>5A0D1055E8A0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2009-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Leukaemia Research Programme Grant</gtr:description><gtr:end>2012-07-02</gtr:end><gtr:fundingOrg>Leukaemia and Lymphoma Research</gtr:fundingOrg><gtr:id>0F4D7C18-0CBF-4598-9FAE-BD15BD20D39D</gtr:id><gtr:outcomeId>5000917FECB0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Pump priming funding</gtr:description><gtr:end>2007-07-02</gtr:end><gtr:fundingOrg>Yorkshire Cancer Research</gtr:fundingOrg><gtr:id>6EBE0927-2D37-4D32-B8F0-CED705D82946</gtr:id><gtr:outcomeId>8E18575A8690</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>YCR project grant</gtr:description><gtr:end>2013-01-02</gtr:end><gtr:fundingOrg>Yorkshire Cancer Research</gtr:fundingOrg><gtr:id>0F501B1B-B260-4351-AEBF-0F83B63CA569</gtr:id><gtr:outcomeId>jSx5KWzbr8j0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>AICR Project Grant</gtr:description><gtr:end>2010-10-02</gtr:end><gtr:fundingOrg>Association for International Cancer Research (AICR)</gtr:fundingOrg><gtr:id>5E741E0A-2C43-4910-82E6-6D7A51C68125</gtr:id><gtr:outcomeId>C224C91D9EF0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have raised a particularly useful set of polyclonal antibodies to an important transcription factor. These work better for certain applications than other antibodies</gtr:description><gtr:id>5B50F961-BED9-436F-8D8F-F19F84466B21</gtr:id><gtr:impact>Contributed to 16901790 18953407</gtr:impact><gtr:outcomeId>10336A0CB1D</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Polyconal antibody to BLIMP1</gtr:title><gtr:type>Antibody</gtr:type><gtr:url>http://europepmc.org/abstract/MED/16901792</gtr:url><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>AA4D84C1-87A2-472D-BA80-1F4123A7492F</gtr:id><gtr:title>An extended set of PRDM1/BLIMP1 target genes links binding motif type to dynamic repression.</gtr:title><gtr:parentPublicationTitle>Nucleic acids research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6fc6da1d29ae4ca40c3da21395c649f7"><gtr:id>6fc6da1d29ae4ca40c3da21395c649f7</gtr:id><gtr:otherNames>Doody GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0305-1048</gtr:issn><gtr:outcomeId>Ph69afjbm2y</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5B95317-C68C-41D8-BF87-E7EF103E3E46</gtr:id><gtr:title>PRDM1/BLIMP-1 modulates IFN-gamma-dependent control of the MHC class I antigen-processing and peptide-loading pathway.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6fc6da1d29ae4ca40c3da21395c649f7"><gtr:id>6fc6da1d29ae4ca40c3da21395c649f7</gtr:id><gtr:otherNames>Doody GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>56A1D120F0D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E39D67CF-E1DA-475C-9C60-13EA0207E4B8</gtr:id><gtr:title>Expression pattern of XBP1(S) in human B-cell lymphomas.</gtr:title><gtr:parentPublicationTitle>Haematologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1931f107266f73a5aac7b9f4c97baabf"><gtr:id>1931f107266f73a5aac7b9f4c97baabf</gtr:id><gtr:otherNames>Maestre L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0390-6078</gtr:issn><gtr:outcomeId>A2E3C027FE8</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D5E4194A-FBA7-44BB-88E4-A9C73EFC0500</gtr:id><gtr:title>Reprogramming primordial germ cells into pluripotent stem cells.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/48266f440a0c1e9db179751d7c1e2cc4"><gtr:id>48266f440a0c1e9db179751d7c1e2cc4</gtr:id><gtr:otherNames>Durcova-Hills G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>52197294946</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17940C54-AA8C-4CF6-966D-FDABD064918F</gtr:id><gtr:title>Repression of IFN-gamma induction of class II transactivator: a role for PRDM1/Blimp-1 in regulation of cytokine signaling.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ca8b0a014f388bcd3bb3d8fbc5fb1248"><gtr:id>ca8b0a014f388bcd3bb3d8fbc5fb1248</gtr:id><gtr:otherNames>Tooze RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>41771BC7DC4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1A02062-04C6-472B-82AB-DDE6219C10F4</gtr:id><gtr:title>BLIMP-1 is a target of cellular stress and downstream of the unfolded protein response.</gtr:title><gtr:parentPublicationTitle>European journal of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6fc6da1d29ae4ca40c3da21395c649f7"><gtr:id>6fc6da1d29ae4ca40c3da21395c649f7</gtr:id><gtr:otherNames>Doody GM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0014-2980</gtr:issn><gtr:outcomeId>54EE316E9F3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E19B3600-9953-485B-B42B-0872E36403B4</gtr:id><gtr:title>Blimp1 defines a progenitor population that governs cellular input to the sebaceous gland.</gtr:title><gtr:parentPublicationTitle>Cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b36dfcdc39aaf9f200e75f344ee3b98f"><gtr:id>b36dfcdc39aaf9f200e75f344ee3b98f</gtr:id><gtr:otherNames>Horsley V</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0092-8674</gtr:issn><gtr:outcomeId>14F31DC27E5</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G108/500</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>